| Management target | Revenue 36.0% |
|---|
| Revenue growth | Revenue ₹43.72 Cr, +72.64% YoY; off soft H1 FY26 base. |
|---|---|
| Margins | Gross margin 51.39% vs 57.88% H2 FY26; EBITDA margin 12.71%. |
| Demand visibility | Demand 'slightly uncertain' per CEO; 12,000 customers touched; 4,700 added H1. |
| Management confidence | Balanced; cautious on margins, yet claims 'assured' decent profitability. |
Growth
Revenue +72.64% YoY on a weak base; gross margin fell to 51.39% from 57.88%. Marketing ₹3.4 Cr.
Outlook
Revenue CAGR ~36% (30s%+ cited); profit CAGR ~40%, no timeframe; Aakaar mix 36-37% by FY27-end.
Risks
Debtor days 219 vs 206; cash ₹1.05 Cr; forex and EU cost pressure; H2 margins unguided.
Earnings Call Transcript filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹71.80
- Market cap
- ₹101.8 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 15.3×Sector 53.8×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies issued a Postal Ballot Notice seeking approval to appoint Mr. Abhash Meswani as Whole-Time Director with ₹50 lakh annual remuneration for five years.
Aakaar Medical Technologies H1 FY27 Results: Turns Profitable, Net Profit ₹3.5 Cr
Aakaar Medical Technologies Ltd reported revenue from operations of ₹43.7 Cr (+72.7% YoY) and net profit of ₹3.5 Cr for H1 FY27.
- Key figure
- Net profit ₹3.5 Cr
Aakaar Medical Technologies Investor Presentation: Key Takeaways
H1 FY27 revenue ₹43.72 Cr (+72.6% YoY), EBITDA ₹5.43 Cr (12.42%), PAT ₹3.54 Cr vs prior loss ₹0.78 Cr. Strategy: doctor-led B2B2C distribution, Xelix clinic network, debtor-days reduction.
Aakaar Medical Technologies Board Meeting Date
Aakaar Medical Technologies Limited will hold a board meeting on 30-Oct-2026 to consider unaudited half-yearly financial results and ESOP matters.
Aakaar Medical Technologies Other Announcement
Aakaar Medical Technologies Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026. The report confirms total issued capital remains at 1,41,72,816 equity shares.
Aakaar Medical Technologies Business Update
Aakaar Medical Technologies provided an operational update for Q1 FY2026-27, detailing expansion in its clinic network, distributor count, and overall sales force effectiveness.